Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
131 hedge funds and large institutions have $553M invested in Intra-Cellular Therapies Inc. in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 26 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
59% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $6.7M
4% less funds holding
Funds holding: 137 → 131 (-6)
14% less capital invested
Capital invested by funds: $643M → $553M (-$89.9M)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.9M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.08M |
| 4 |
SC
Samlyn Capital
New York
|
+$3.94M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$15.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.4M |
| 3 |
PA
Perceptive Advisors
New York
|
-$14.7M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$10.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.66M |
ITCI Hedge Fund Activity: Q4 2017 in Review
131 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2017, worth a combined $553M — down 14% from $643M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ITCI and 20 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 54 added.
The largest buyer was BlackRock, adding an estimated $10.9M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $15.8M sold.
- 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2017, down from 137 in Q3 2017.
- Funds reported $553M of Intra-Cellular Therapies Inc. stock for Q4 2017, down 14% quarter-over-quarter.
- 20 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2017 and 26 closed out, a net change of -6 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2017 was BlackRock, an estimated $10.9M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2017 was Hillhouse Investment Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q4 2017.